Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Asciminib, the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (CML-CP) treated with ≥2 prior tyrosine kinase inhibitors (TKIs). In...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochhaus, Andreas, Réa, Delphine, Boquimpani, Carla, Minami, Yosuke, Cortes, Jorge E., Hughes, Timothy P., Apperley, Jane F., Lomaia, Elza, Voloshin, Sergey, Turkina, Anna, Kim, Dong-Wook, Abdo, Andre, Fogliatto, Laura Maria, le Coutre, Philipp, Sasaki, Koji, Kim, Dennis Dong Hwan, Saussele, Susanne, Annunziata, Mario, Chaudhri, Naeem, Chee, Lynette, García-Gutiérrez, Valentin, Kapoor, Shruti, Allepuz, Alex, Quenet, Sara, Bédoucha, Véronique, Mauro, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991909/
https://www.ncbi.nlm.nih.gov/pubmed/36717654
http://dx.doi.org/10.1038/s41375-023-01829-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991909/
https://www.ncbi.nlm.nih.gov/pubmed/36717654
http://dx.doi.org/10.1038/s41375-023-01829-9

Ejemplares similares